Lidia Moreira Lima

List of Publications by Year
in descending order

109 papers	3,202 citations	236612 25 h-index	168136 53 g-index
112 all docs	112 docs citations	112 times ranked	4626 citing authors

#	Article	IF	Citations
1	Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design. Current Medicinal Chemistry, 2005, 12, 23-49.	1.2	563
2	Î²-lactam antibiotics: An overview from a medicinal chemistry perspective. European Journal of Medicinal Chemistry, 2020, 208, 112829.	2.6	227
3	Synthesis and analgesic activity of novel N-acylarylhydrazones and isosters, derived from natural safrole##This paper represents contribution # 36 of the LASSBio, UFRJ (Br.) (LASSBio,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 66 Chemistry, 2000, 35, 187-203.	2.6	195
4	Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorganic and Medicinal Chemistry, 2002, 10, 3067-3073.	1.4	174
5	N-Acylhydrazones as drugs. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2797-2806.	1.0	140
6	Selective activity against Mycobacterium tuberculosis of new quinoxaline 1,4-di-N-oxides. Bioorganic and Medicinal Chemistry, 2009, 17, 385-389.	1.4	112
7	Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. European Journal of Medicinal Chemistry, 2014, 71, 1-14.	2.6	109
8	Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorganic and Medicinal Chemistry, 2009, 17, 641-652.	1.4	94
9	Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1169-1172.	1.0	70
10	Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2012, 20, 2158-2171.	1.4	62
11	Synthesis and anti-platelet activity of novel arylsulfonateâ€“acylhydrazone derivatives, designed as antithrombotic candidates. European Journal of Medicinal Chemistry, 2008, 43, 348-356.	2.6	60
12	Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates. European Journal of Medicinal Chemistry, 2013, 59, 64-74.	2.6	57
13	New oxidovanadium(IV) N -acylhydrazone complexes: Promising antileishmanial and antitrypanosomal agents. European Journal of Medicinal Chemistry, 2013, 62, 20-27.	2.6	57
14	Synthesis and structureâ€“activity relationship of 3-phenylquinoxaline 1,4-di-N-oxide derivatives as antimalarial agents. European Journal of Medicinal Chemistry, 2008, 43, 1903-1910.	2.6	53
15	Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates. Bioorganic and Medicinal Chemistry, 2010, 18, 5007-5015.	1.4	53
16	Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury. European Respiratory Journal, 2003, 22, 20-27.	3.1	50
17	Docking, Synthesis and Antiproliferative Activity of N-Acylhydrazone Derivatives Designed as Combretastatin A4 Analogues. PLoS ONE, 2014, 9, e85380.	1.1	50
18	Design, Synthesis, and Pharmacological Evaluation of Novel Hybrid Compounds to Treat Sickle Cell Disease Symptoms. Part II: Furoxan Derivatives. Journal of Medicinal Chemistry, 2012, 55, 7583-7592.	2.9	49

#	Article	IF	Citations
19	Analgesic and Anti-Inflammatory Activities of Salicylaldehyde 2-Chlorobenzoyl Hydrazone (H2LASSBio-466), Salicylaldehyde 4-Chlorobenzoyl Hydrazone (H2LASSBio-1064) and Their Zinc(II) Complexes. Molecules, 2011, 16, 6902-6915.	1.7	48
20	Binuclear zinc(II) complexes with the anti-inflammatory compounds salicylaldehyde semicarbazone and salicylaldehyde-4-chlorobenzoyl hydrazone (H2LASSBio-1064). Polyhedron, 2011, 30, 1891-1898.	1.0	39
21	Novel Orally Active Analgesic and Anti-Inflammatory Cyclohexyl-N-Acylhydrazone Derivatives. Molecules, 2015, 20, 3067-3088.	1.7	39
22	Design, Synthesis, and Pharmacological Evaluation of Novel Hybrid Compounds To Treat Sickle Cell Disease Symptoms. Journal of Medicinal Chemistry, 2011, 54, 5811-5819.	2.9	38
23	N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity. International Journal of Cardiology, 2014, 173, 154-162.	0.8	36
24	Natural products as new antimitotic compounds for anticancer drug development. Clinics, 2018, 73, e813s.	0.6	33
25	A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. Scientific Reports, 2019, 9, 14.	1.6	28
26	Synthesis, Biological Evaluation, and Structureâ€“activity Relationship of Clonazepam, Meclonazepam, and 1,4â€Benzodiazepine Compounds with Schistosomicidal Activity. Chemical Biology and Drug Design, 2012, 79, 943-949.	1.5	26
27	Can LASSBio 596 and dexamethasone treat acute lung and liver inflammation induced by microcystin-LR?. Toxicon, 2010, 56, 604-612.	0.8	25
28	Novel phthalimide derivatives, designed as leukotriene D4 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1533-1535.	1.0	24
29	Antiplasmodial structureâ€“activity relationship of 3-trifluoromethyl-2-arylcarbonylquinoxaline 1,4-di-N-oxide derivatives. Experimental Parasitology, 2008, 118, 25-31.	0.5	23
30	Discovery of naphthylâ€Nâ€acylhydrazone p38Î± MAPK inhibitors with in vivo antiâ€inflammatory and antiâ€TNFâ€Î± activity. Chemical Biology and Drug Design, 2018, 91, 391-397.	1.5	22
31	The effects of 3-methylclonazepam on Schistosoma mansoni musculature are not mediated by benzodiazepine receptors. European Journal of Pharmacology, 2009, 606, 9-16.	1.7	21
32	Homologation: A Versatile Molecular Modification Strategy to Drug Discovery. Current Topics in Medicinal Chemistry, 2019, 19, 1734-1750.	1.0	21
33	LASSBio 596 per os avoids pulmonary and hepatic inflammation induced by microcystin-LR. Toxicon, 2011, 58, 195-201.	0.8	20
34	Design, Synthesis, Antinociceptive and Anti-Inflammatory Activities of Novel Piroxicam Analogues. Molecules, 2012, 17, 14126-14145.	1.7	20
35	LASSBio-468: a new achiral thalidomide analogue which modulates TNF-Î± and NO production and inhibits endotoxic shock and arthritis in an animal model. International Immunopharmacology, 2005, 5, 485-494.	1.7	19
36	Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma. Brazilian Journal of Medical and Biological Research, 2006, 39, 283-287.	0.7	19

#	Article	IF	Citations
37	Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema. Frontiers in Physiology, 2015, 6, 267.	1.3	18
38	Design, synthesis and inÂvitro trypanocidal and leishmanicidal activities of novel semicarbazone derivatives. European Journal of Medicinal Chemistry, 2015, 100, 24-33.	2.6	18
39	Synthesis and pharmacological evaluation of N-phenyl-acetamide sulfonamides designed as novel non-hepatotoxic analgesic candidates. European Journal of Medicinal Chemistry, 2009, 44, 3612-3620.	2.6	17
40	Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: InÂvitro and inÂvivo preclinical studies. European Journal of Medicinal Chemistry, 2020, 204, 112492.	2.6	16
41	COVID-19: Physiopathology and Targets for Therapeutic Intervention. Revista Virtual De Quimica, 2020, 12, 1464-1497.	0.1	16
42	Mutagenicity of New Lead Compounds to Treat Sickle Cell Disease Symptoms in a Salmonella/Microsome Assay. International Journal of Molecular Sciences, 2010, 11, 779-788.	1.8	14
43	Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation. Pharmacological Reports, 2011, 63, 1029-1039.	1.5	14
44	Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists. Current Topics in Medicinal Chemistry, 2012, 12, 2037-2048.	1.0	14
45	Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors. European Journal of Medicinal Chemistry, 2012, 54, 264-271.	2.6	14
46	The molecular basis for coxib inhibition of p38Î± MAP kinase. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3506-3509.	1.0	13
47	Therapeutic approaches for tumor necrosis factor inhibition. Brazilian Journal of Pharmaceutical Sciences, 2011, 47, 427-446.	1.2	13
48	Synthesis of new lophineâ€“carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling. MedChemComm, 2019, 10, 2089-2101.	3.5	13
49	Comparative use of solvent-free KF-A12O3and K2CO3in acetone in the synthesis of quinoxaline 1,4-dioxide derivatives designed as antimalarial drug candidates. Journal of Heterocyclic Chemistry, 2005, 42, 1381-1385.	1.4	12
50	Potential Inhibitory Effect of LASSBio-596, a New Thalidomide Hybrid, on Inflammatory Corneal Angiogenesis in Rabbits. Ophthalmic Research, 2012, 48, 177-185.	1.0	12
51	Structure Re-determination of LASSBio-294 â€“ a cardioactive compound of the N-acylhydrazone class â€“ using X-ray powder diffraction data. Powder Diffraction, 2013, 28, S491-S509.	0.4	12
52	Synthesis, solubility, plasma stability, and pharmacological evaluation of novel sulfonylhydrazones designed as anti-diabetic agents. Drug Design, Development and Therapy, 2016, Volume 10, 2869-2879.	2.0	12
53	O-Alkylation of Bioactive Phthalimide Derivatives Under Microwave Irradiation in Dry Media. Synthetic Communications, 2000, 30, 3291-3306.	1.1	11
54	Vasodilatory activity and antihypertensive profile mediated by inhibition of phosphodiesterase type 1 induced by a novel sulfonamide compound. Fundamental and Clinical Pharmacology, 2012, 26, 690-700.	1.0	11

#	Article	IF	Citations
55	Investigating the therapeutic effects of LASSBio-596 in an inÂvivo model of cylindrospermopsin-induced lung injury. Toxicon, 2015, 94, 29-35.	0.8	11
56	QuÃmica Medicinal Moderna: desafios e contribuiÃ§Ã£o brasileira. Quimica Nova, 2007, 30, 1456-1468.	0.3	10
57	Synthesis, pharmacological evaluation and docking studies of new sulindac analogues. European Journal of Medicinal Chemistry, 2009, 44, 1959-1971.	2.6	10
58	3-Aminothiophene-2-Acylhydrazones: Non-Toxic, Analgesic and Anti-Inflammatory Lead-Candidates. Molecules, 2014, 19, 8456-8471.	1.7	10
59	Non-competitive inhibitor of nucleoside hydrolase from Leishmania donovani identified by fragment-based drug discovery. RSC Advances, 2016, 6, 87738-87744.	1.7	10
60	Respiratory and Systemic Effects of LASSBio596 Plus Surfactant in Experimental Acute Respiratory Distress Syndrome. Cellular Physiology and Biochemistry, 2016, 38, 821-835.	1.1	10
61	Structural characterization and cytotoxicity studies of different forms of a combretastatin A4 analogue. Journal of Molecular Structure, 2017, 1147, 226-234.	1.8	10
62	Synthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 Inhibitors. PLoS ONE, 2016, 11, e0162895.	1.1	10
63	New antithrombotic aryl-sulfonylthiosemicarbazide derivatives synthesized from natural safrole. Journal of the Brazilian Chemical Society, 1999, 10, 421-428.	0.6	9
64	Enzymatic hydrolysis by immobilized lipase applied to a new prototype anti-asthma drug. Biochemical Engineering Journal, 2004, 21, 103-110.	1.8	9
65	Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model. European Journal of Pharmacology, 2012, 690, 176-182.	1.7	9
66	Synthesis and Pharmacological Evaluation of Novel Phenyl Sulfonamide Derivatives Designed as Modulators of Pulmonary Inflammatory Response. Molecules, 2012, 17, 14651-14672.	1.7	9
67	Beyond Bioisosterism: New Concepts in Drug Discovery. , 2017, , 186-210.		9
68	Beirut Reaction and its Application in the Synthesis of Quinoxaline-N,N'-Dioxides Bioactive Compounds. Revista Virtual De Quimica, 2013, 5, .	0.1	9
69	Semicarbazone derivatives as promising therapeutic alternatives in leishmaniasis. Experimental Parasitology, 2019, 201, 57-66.	0.5	8
70	Synthesis, Biological Evaluation and Molecular Docking of New Benzenesulfonylhydrazone as Potential anti-Trypanosoma cruzi Agents. Medicinal Chemistry, 2017, 13, 149-158.	0.7	8
71	NSAIDs revisited: Putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARÎ³). European Journal of Medicinal Chemistry, 2008, 43, 1918-1925.	2.6	7
72	Unexpected Reduction of Ethyl 3-Phenylquinoxaline-2- carboxylate 1,4-Di-N-oxide Derivatives by Amines. Molecules, 2008, 13, 78-85.	1.7	7

#	Article	IF	Citations
73	Oral Antithrombotic Effects of Acylhydrazone Derivatives. Journal of Atherosclerosis and Thrombosis, 2013, 20, 287-295.	0.9	7
74	LASSBio-596 protects gastric mucosa against the development of ethanol-induced gastric lesions in mice. European Journal of Pharmacology, 2019, 863, 172662.	1.7	7
75	Safrole and the Versatility of a Natural Biophore. Revista Virtual De Quimica, 2015, 7, .	0.1	7
76	Toxicological in vitro and subchronic evaluation of LASSBio-596. Food and Chemical Toxicology, 2014, 73, 148-156.	1.8	6
77	Structural feature evolution â€“ from fluids to the solid phase â€“ and crystal morphology study of LASSBio 1601: a cyclohexyl-N-acylhydrazone derivative. RSC Advances, 2015, 5, 39889-39898.	1.7	6
78	Structural and physicochemical characterization of sulfonylhydrazone derivatives designed as hypoglycemic agents. New Journal of Chemistry, 2017, 41, 6464-6474.	1.4	6
79	Lung and liver responses to 1- and 7-day treatments with LASSBio-596 in mice subchronically intoxicated by microcystin-LR. Toxicon, 2018, 141, 1-8.	0.8	6
80	Synchrotron X-ray powder diffraction data of LASSBio-1515: A new N-acylhydrazone derivative compound. Radiation Physics and Chemistry, 2014, 95, 292-295.	1.4	5
81	Preliminary evaluation of the encapsulation of new antidiabetic sulphonylhydrazone and antitumor N-acylhydrazone derivatives using PLGA nanoparticles. Journal of Physics: Conference Series, 2015, 617, 012015.	0.3	5
82	LASSBio-1586, an N-acylhydrazone derivative, attenuates nociceptive behavior and the inflammatory response in mice. PLoS ONE, 2018, 13, e0199009.	1.1	5
83	Reduction of cardiac and renal dysfunction by new inhibitor of DPP4 in diabetic rats. Pharmacological Reports, 2019, 71, 1190-1200.	1.5	5
84	Oxidative imbalance in mice intoxicated by microcystin-LR can be minimized. Toxicon, 2018, 144, 75-82.	0.8	4
85	Synthesis, Pharmacological Evaluation and Docking Study of a New Modulator of Microtubule Polymerization. Letters in Drug Design and Discovery, 2018, 15, 778-786.	0.4	4
86	New Benzofuran N-Acylhydrazone Reduces Cardiovascular Dysfunction in Obese Rats by Blocking TNF-Alpha Synthesis . Drug Design, Development and Therapy, 2020, Volume 14, 3337-3350.	2.0	4
87	In Vitro Microsomal Hepatic Metabolism of Antiasthmatic Prototype LASSBio-448. Current Topics in Medicinal Chemistry, 2014, 14, 1388-1398.	1.0	4
88	Assessment of the In Vivo Genotoxicity of New Lead Compounds to Treat Sickle Cell Disease. Molecules, 2011, 16, 2982-2989.	1.7	3
89	A combined experimental and in silico characterization to highlight additional structural features and properties of a potentially new drug. Journal of Molecular Structure, 2017, 1146, 735-743.	1.8	3
90	The antithrombotic and haemostatic effects of LASSBio-752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats. Journal of Pharmacy and Pharmacology, 2017, 69, 1374-1380.	1.2	3

#	Article	IF	Citations
91	Leishmanicidal candidate LASSBio-1736, a cysteine protease inhibitor with favorable pharmacokinetics: low clearance and good distribution. Xenobiotica, 2018, 48, 1258-1267.	0.5	3
92	Synthesis, X-ray diffraction study and pharmacological evaluation of 3-amino-4-methylthiophene-2-acylcarbohydrazones. Anais Da Academia Brasileira De Ciencias, 2018, 90, 1073-1088.	0.3	3
93	Synthesis, Aqueous Solubility, Metabolic Stability and Pharmacological Profile of Simplified Urea Derivatives. Letters in Drug Design and Discovery, 2018, 15, 766-777.	0.4	3
94	Evaluating the prophylactic potential of the phtalimide derivative LASSBio 552 on allergen-evoked inflammation in rats. European Journal of Pharmacology, 2005, 511, 219-227.	1.7	2
95	Carbamoyl-N-aryl-imine-urea: a new framework to obtain a putative leishmanicidal drug-candidate. RSC Advances, 2020, 10, 12384-12394.	1.7	2
96	Agentes antiasmÃ¡ticos modernos: antagonistas de receptores de leucotrienos cisteÃ¤nicos. Quimica Nova, 2002, 25, 825-834.	0.3	1
97	Cardiovascular Effects of a Novel Synthetic Analogue of Naturally Occurring Piperamides. Journal of Cardiovascular Pharmacology, 2010, 56, 293-299.	0.8	1
98	Analgesic and Anti-Inflammatory Properties of Arylnitroalkenes. Inflammation and Allergy: Drug Targets, 2015, 14, 19-28.	1.8	1
99	Simple HPLCâ€UV for the quantification of a new leishmanicidal candidate (E)â€1â€4(trifluoromethyl) assessment. Biomedical Chromatography, 2016, 30, 1029-1035.	0.8	1
100	Design, synthesis, and biological evaluation of new thalidomideâ€“donepezil hybrids as neuroprotective agents targeting cholinesterases and neuroinflammation. RSC Medicinal Chemistry, 0, , .	1.7	1
101	Cardiovascular effects induced by N-(4'-dihydro)-piperoylthiomorpholine in normotensive rats. Journal of Pharmacy and Pharmacology, 2010, 62, 1794-1800.	1.2	0
102	LASSBio-542: Novel Thalidomide Analog Distinctly Modulates IL-10 and Inhibits Angiogenesis. Current Bioactive Compounds, 2012, 8, 167-175.	0.2	0
103	Multi-gram Preparation of 7-Nitroquinoxalin-2-amine. Journal of the Brazilian Chemical Society, 0, , .	0.6	0
104	Design and Synthesis In Silico Drug-like Prediction and Pharmacological Evaluation of Cyclopolymethylenic Homologous of LASSBio-1514. Molecules, 2021, 26, 4828.	1.7	0
105	LASSBio-596: a New Pre-clinical Candidate for Rheumatoid Arthritis?. Inflammation, 2022, 45, 528-543.	1.7	0
106	Novel Hybrids of Hydroxyurea and Thalidomide Based Pharmacophores Induce Fetal Hemoglobin and Block Monocyte Activation. Blood, 2010, 116, 2673-2673.	0.6	0
107	Novel 1,2,5-Oxadiazole 2-Oxide Derivatives with Analgesic and Fetal Hemoglobin Induced Properties Designed As Drug Candidate to Treat Sickle Cell Disease Symptoms. Blood, 2011, 118, 2137-2137.	0.6	0
108	Testimonials from Ex-students and Collaborators. Revista Virtual De Quimica, 2013, 5, .	0.1	0

#	Article	IF	Citations
109	LASSBio 596 improves function, inflammation and apoptosis in lung and liver of mice intoxicated with microcystin-LR. , 2015, , .		0